anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention provides a novel corona vaccine vector and application thereof. Consists of SARS-CoV-2RBD as antigen and a STING agonist, diabZI, coupled to yeast beta-glucan particles. The GP-diABZI-RBD vaccine showed sustained vaccine release and elicited a more sustained immune response in mice compared to the diABZI-RBD vaccine alone. Intraperitoneal injection of GP-DiabZI-RBD in mice can elicit significant cellular and humoral immune responses. Using a pseudovirion-based replication-competent virus-like particle system, we determined that this vaccine could effectively induce potent and durable neutralizing antibodies against prototypes and VOCs, respectively. In particular, the GP-dianzi-RBD vaccine provides a prototype RBD antigen that exhibits a stronger and longer humoral immune response and antiviral protection.
Omeprazole 40 mg/day + Circadin 6 mg/12 hours. Patients will take the Omeprazole capsule once in the morning before breakfast together with 3 tables of 2 mgs of Circadin (melatonin). In the evening, before dinner, patients will take 3 tablets of 2 mg of Circadin.
Trimodal therapy (TMT) is accepted as an NCCN category 1 alternative to radical cystectomy (with neoadjuvant chemotherapy) in patients with cT2N0M0 muscle-invasive urothelial cell bladder cancer (MIBC). Not all patients with MIBC have pure urothelial cell carcinoma; urothelial carcinoma with variant histology (VH) described any morphologic variant of conventional urothelial carcinoma that is believed to be derived from urothelial carcinoma and is typically admixed with conventional urothelial carcinoma in the same tumor. Variant histologies described include squamous differentiation, glandular differentiation, micropapillary, sarcomatoid, small cell/neuroendocrine, plasmacytoid and nested variant. This is a rare tumor type and understudied. For patients with variant histologies there is limited data on the use of trimodal therapy. There are a couple single institution retrospective studies and data from the NCDB, but no prospective data.
Cardiovascular disease is the leading cause of death in the US. While secondary prevention approaches have improved longevity of patients, risk factors and adverse health behaviors (e.g., physical inactivity, smoking) are highly prevalent, and in most contemporary series, less than 1% of adults meet all factors of ideal CV health. The logistics and practicalities of meeting the goal of ideal CV health have not been clearly elucidated. Practice guidelines recommend using the Framingham risk score (FRS) or other risk prediction tools to classify patients' risk of CV disease. These models however are imprecise and there is increasing focus on identifying markers that provide better measures of risk. As digital platforms are increasingly used to document lifestyle and health behaviors, data from digital sources may provide a window into manifestations of novel risk factors and potentially a better characterization of existing risk factors. While it seems like a cliche to mention the profound impact of digital data on everyday lives, there is indeed great substance in the opportunities these new media provide for understanding behavioral, social, and environmental determinants of health. This project seeks to identify and characterize features derived from digital data (e.g. social media, online search, mobile media) which are associated with coronary heart disease (CHD) and related risk factors, and develop models that use digital data and conventional predictive models to predict CHD risk and health care utilization.
Participants will be provided a writing prompt that describes their self-reported drinking, then asks them to write for 5 to 10 minutes about how that drinking is associated with their self-reported religious identity. After completing that writing assignment, participants will be shown their response, and asked to spend 5 to 10 minutes describing how their drinking behaviors in the next month might change.
Cerebral venous sinus thrombosis (CVST) is an uncommon venous thromboembolic event accounting for <1% of strokes resulting in brain parenchymal injuries. JAK2V617F mutation, the most frequent driving mutation of myeloproliferative neoplasms, has been reported to be associated with worse clinical outcomes in patients with CVST. We investigated whether hematopoietic JAK2V617F expression predisposes to specific pathophysiological processes and/or worse prognosis after CVST. Using an in vivo mouse model of CVST, we analyzed clinical, biological, and imaging outcomes in mice with hematopoietic-restricted Jak2V617F expression, compared with wild-type Jak2 mice. In parallel, we studied a human cohort of JAK2V617F-positive or -negative CVST. Early after CVST, mice with hematopoietic Jak2V617F expression had increased adhesion of platelets and neutrophils in cerebral veins located in the vicinity of CVST. On day 1, Jak2V617F mice had a worse outcome characterized by significantly more frequent and severe intracranial hemorrhages (ICHs) and higher mortality rates. Peripheral neutrophil activation was enhanced, as indicated by higher circulating platelet-neutrophil aggregates, upregulated CD11b expression, and higher myeloperoxydase plasma level. Concurrently, immunohistological and brain homogenate analysis showed higher neutrophil infiltration and increased blood-brain barrier disruption. Similarly, patients with JAK2V617F-positive CVST tended to present higher thrombotic burden and had significantly higher systemic immune-inflammation index, a systemic thromboinflammatory marker, than patients who were JAK2V617F-negative. In mice with CVST, our study corroborates that Jak2V617F mutation leads to a specific pattern including increased thrombotic burden, ICH, and mortality. The exacerbated thromboinflammatory response, observed both in mice and patients positive for JAK2V617F, could contribute to hemorrhagic complications.
BACKGROUND: Craniosynostosis is a prevalent craniofacial malformation in Finland; however, comprehensive population-based epidemiological data are limited. This study aimed to estimate the total and birth prevalence of craniosynostosis in Finland from 1987 to 2010 and examine temporal trends.
METHODS: We collected the data from nationwide registers maintained by the Finnish Institute for Health and Welfare and Statistics Finland, as well as treating hospitals, encompassing live births, stillbirths, terminations for fetal anomalies, and infant deaths with suspected or diagnosed craniosynostosis or skull deformation. A craniofacial surgeon and a clinical geneticist reviewed 1878 medical records for diagnostic confirmation.
RESULTS: Out of 877 craniosynostosis cases, 83% were single-suture synostoses (all live births), 10% craniosynostosis syndromes, and 7% multisutural non-syndromic synostoses. Live birth prevalence from 1987 to 2010 was 6.0/10,000 live births, ranging from 5.0/10,000 in 1987 to 7.5/10,000 in 2010. Total prevalence, including live births, stillbirths, and terminations, varied from 5.0/10,000 in 1987 to 8.0/10,000 in 2010. Sagittal synostosis was the most common synostosis, with a prevalence of 3.9/10,000 live births, followed by metopic (0.6/10,000), unicoronal (0.4/10,000), and unilambdoid (0.1/10,000) synostoses.
CONCLUSIONS: The total combined prevalence of all craniosynostosis types significantly increased driven by a nonsignificant rise across all subgroups and a significant increase in the syndrome group. In live births increase was significant only within the syndrome subgroup, primarily due to an increase in Muenke syndrome patients. The rising prevalence of syndromes necessitates further investigation. Contrasting with trends in Europe, Australia, and the USA, Finland showed no significant increase in metopic craniosynostosis.
18 healthy volunteers will be randomized and will start the study. The study will last 4 weeks for each subject. The first week will be a week of adaptation (or run-in period) to the diet which they will have to follow for the duration of study. During this period, they will collect 2 samples of stools and urine. Then subjects will alternate 4 days of diet either with ham, or with ham and calcium, or with ham enriched with vitamin E. At least, 3 days will separate every period (wash-out) of nutritional intervention. Urines and stools will be collected last 3 days of every interventional period and also last day of every wash out period.
A composition including a pyrithione polyvalent metal salt, a surfactant, and water, wherein the surfactant in the pyrithione polyvalent metal salt-containing composition is a compound represented by general formula (1). (In general formula (1), R1 represents an optionally substituted C7-21 alkyl group or a coconut oil fatty acid residue. R2 represents a C1-3 alkylene group. X1 represents a monovalent cation. Z represents a hydrogen atom or -R3COOX2. R3 represents a C1-3 alkylene group. X2 represents a monovalent cation.
BACKGROUND: Deep sternal wound infection (DSWI) constitutes a serious complication after coronary artery bypass grafting (CABG) surgery. The aim of this study is to evaluate the dose-response relationship between glycated hemoglobin (HbA1c) level and the risk of DSWI after CABG.
METHODS: PubMed, Scopus, and Cochrane Library databases were searched to identify potentially relevant articles. According to rigorous inclusion and exclusion criteria, fourteen studies including 15,570 patients were enrolled in our meta-analysis. Odds ratio (OR) with 95% confidence intervals (CIs) was used as the summary statistic. The robust-error meta-regression model was used to synthesize the dose-response relationship.
RESULTS: Our meta-analysis shows that among patients undergoing CABG, preoperative elevated HbA1c was associated with the risk of developing DSWI (OR = 2.67, 95% CI 2.00-3.58) but with low prognostic accuracy (diagnostic OR = 2.70, 95% CI 1.96-3.73; area under the curve = 0.66, 95% CI 0.62-0.70) for predicting postoperative DSWI. Subgroup analyses showed the relationship became nonsignificant in patients without diabetes and studies adopting lower HbA1c thresholds. Dose-response analysis showed a significant nonlinear (p = 0.03) relationship between HbA1c and DSWI, with a significantly increased risk of DSWI when HbA1c was > 5.7%.
CONCLUSIONS: An elevated HbA1c level of > 5.7% was related to a higher risk of developing DSWI after CABG, and the risk increased as the HbA1c level grew. The association between HbA1c and DSWI was nonsignificant among nondiabetic patients while significant among diabetic patients.
PURPOSE:To obtain anti-HIVagent remarkably inhibit formation of a giant cell generated from fusion of HIV-infected cell with non-infected cell by containing chemically modified protein in which polarity of charge at functional group in amino acid residual side chain of a plasma protein is chemically modified as active ingredient. CONSTITUTION:Functional group in amino acid residual side chain of a plasma protein, e.g. amino group is converted to a group expressed by the formula NHCORCOO<-> (R is organic group) using dicarboxylic acid anhydride (e.g. maleic anhydride), or treated with a phosphate containing aldehyde group (e.g. pyridoxal phosphate) and reduced to a group expressed by the formula NHCH2ROPO3<->. Thiol group is converted to a group expressed by the formula S-S-SO3<-> using tetrathionic acid compound to modify polarity of electric charge to negative, and the chemically modified protein is contained in the subject agent as active ingredient. As the plasma protein, human serum albumin, human immunoglobulin, human transferrin, human fibrinogen or bovine serum albumin is used.
A Chinese patent medicine for treating mammary gland diseases and a preparation method thereof belong to the field of traditional Chinese medicines. The traditional Chinese medicine composition is prepared from the following traditional Chinese medicinal materials in parts by weight: 1-7 parts of radix bupleuri, 1-6 parts of spina gleditsiae, 1-6 parts of cowherb seed, 1-8 parts of selfheal, 1-7 parts of red paeony root, 1-6 parts of radix curcumae, 1-4 parts of oyster, 1-5 parts of salvia miltiorrhiza, 1-5 parts of tangerine seed, 1-5 parts of rhizoma sparganii, 0.3-2 parts of curcuma zedoary and 0.3-2 parts of liquorice. The invention treats both qi and blood and phlegm and blood stasis, has the effects of dispersing stagnated liver qi, regulating qi, promoting blood circulation to stop pain, reducing phlegm and resolving masses. Thus, it can be gradually dissipated and fully absorbed in the case of lump in breast. The invention has low cost, convenient use, quick response and obvious effect, and can achieve the effect of radical treatment without relapse. For lump in breast, breast pain; the traditional Chinese medicine composition has good curative effects on hyperplasia of mammary glands and mastitis, the total effective rate is 93.9%, and animal test results show that the traditional Chinese medicine composition is low in toxicity and safe in clinical medication.
The present invention relates to an antioxidant, whitening, anti-wrinkle, or anti-inflammatory composition including a Schisandra chinensis extract. The composition including a Schisandra chinensis extract as an active ingredient has excellent DPPH free radical removing activities and has an antioxidant effect. The composition has a tyrosinase inhibiting effect, and thus has a whitening effect. Also, the composition enhances collagen activities, and thus has a wrinkle alleviating effect. The composition inhibits NO generation and inflammatory cytokine generation, and thus has an anti-inflammatory effect. In addition, a Schisandra chinensis extract of the present invention can be safely used for a cosmetic material or a food composition without cytotoxicity and skin side effects.
STRICT ASEPTIC TECHNIQUE IS MANDATORY. The vial should be shaken before use to ensure a uniform suspension. Prior to withdrawal, the suspension should be inspected for clumping or granular appearance (agglomeration). An agglomerated product results from exposure to freezing temperatures and should not be used. After withdrawal, inject without delay to prevent settling in the syringe.

###  Injection Technique

For treatment of joints, the usual intra-articular injection technique should be followed. If an excessive amount of synovial fluid is present in the joint, some, but not all, should be aspirated to aid in the relief of pain and to prevent undue dilution of the steroid.

With intra-articular administration, prior use of a local anesthetic may often be desirable. Care should be taken with this kind of injection, particularly in the deltoid region, to avoid injecting the suspension into the tissues surrounding the site, since this may lead to tissue atrophy.

In treating acute nonspecific tenosynovitis, care should be taken to ensure that the injection of Kenalog-10 Injection is made into the tendon sheath rather than the tendon substance. Epicondylitis may be treated by infiltrating the preparation into the area of greatest tenderness.

###  Intralesional

For treatment of dermal lesions, Kenalog-10 Injection should be injected directly into the lesion, i.e., intradermally or subcutaneously. For accuracy of dosage measurement and ease of administration, it is preferable to employ a tuberculin syringe and a small-bore needle (23-25 gauge). Ethyl chloride spray may be used to alleviate the discomfort of the injection.
PURPOSE: A process of preparing an aromatic agent composition by using ground several medicinal plants and a receiving pouch containing the composition therein are provided. The composition enhances blood circulation and metabolism of human body by attachment to the navel. CONSTITUTION: About 11.5% by weight of olibanum, 11.56% by weight of Eucommia ulmoides, 11.56% by weight of Paeonia lactiflora, 11.56% by weight of Angelicae gigantis radix, 5.78% by weight of Angelicae Dahuricae radix, 1.16% by weight of Cinnamomum cassia, 5.78% by weight of Armeniacae semen, 5.78% by weight of Cnidii Rhizoma, 5.78% by weight of Leonuri Herba, 2.95% by weight of Sorbaria sorbifolia var. stellipila Max., 3.47% by weight of Polygonum avicular L., 11.56% by weight of Poria cocos, 3.47% by weight of Cinnamomi Ramulus, 2.31% by weight of Borneolum and 5.7% by weight of nard are mixed. In the pretreatment process, the Cinnamomum cassia, Cnidii Rhizoma and Angelicae gigantis radix are roasted at 70 to 200deg.C and ground and the Eucommia ulmoides is steamed at 100deg.C, dried under sunlight and ground to 20 to 80 mesh. The composition is attached to the navel(Shinkweon-hyeol(acupoint) as a spot on the body for acupuncture, Korean native name) to improve health.
Participants will receive IV infusion of rituximab once weekly from Week 1 to 4. Participants will also receive one pulse of methylprednisolone, followed by a tapering dose of oral prednisolone at the discretion of the investigator. Methylprednisolone may be repeated up to total of 3 pulses at the discretion of the investigator.
Participants undergo pap smear, uterine lavage, and collection of tumor sample during a planned surgery. DNA is then extracted from the samples and sequenced for TP53 mutations using Crispr-Duplex sequencing.
Numerous studies point to an increased serotoninergic activity in schizophrenia. Additionally, patients with schizophrenia often show reduced filtering of sensory information, which is reflected in reduced P50 suppression and reduced prepulse inhibition of the startle refex (PPI). Currently, the reports in literature on the effects of serotonergic agonists on sensory gating in humans are inconclusive. In an initial study performed in our laboratory, however, we found reduced P50 suppression following administration of imipramine (a combined serotonin- and noradrenalin reuptake inhibitor) to healthy volunteers. This result provides evidence for the involvement of either serotonergic, noradrenergic, or a combination of both pathways in sensory gating. In numerous animal studies however, sensory gating is reduced by agonists of 5-HT, which suggests a serotonergic, rather than a noradrenergic, involvement in sensory gating. Therefore, in a follow-up study, the effects of a selective serotonin reuptake inhibitor (escitalopram) will be investigated on sensory gating parameters of healthy volunteers. To further extend the data of our initial study, the subjects will additionally be tested for two more psychophysiological parameters of attention that are usually found to be disturbed in patients with schizophrenia, i.e. mismatch negativity and selective attention. The design will be a double blind, placebo controlled experiment, in which a single dose of escitalopram or placebo will be given to healthy, non-smoking male volunteers on two occasions, separated by at least a week, after which the subjects will be tested in the psychophysiological test battery.
PROBLEM TO BE SOLVED: To provide a hair cosmetic excellent in portability which can sufficiently remove dirt on both of the hair and scalp without any tools.SOLUTION: The hair cosmetic of the invention comprises the following (A) and (B). The impregnation of (B) into (A) is from 6 g or more to 25 g or less per one sheet of (A). (A) A sheet having a bending resistance of from 10 mm or more to 70 mm or less measured by 45 degree cantilever method in accordance with JIS L1096 :2010, containing cellulosic fibers. (B) A Cosmetic. It is suitable that (A) impregnated with (B) is contained in (C). (C) An outer container having an opening and closing lid which covers a content outlet port to seal the content. An area of the content outlet port is from 25 mmor more to 4000 mmor less.
Psychiatric Adverse Reactions   
Fluoroquinolones, including Levofloxacin in 5% Dextrose Injection, have been associated with an increased risk of psychiatric adverse reactions, including: toxic psychoses, hallucinations, or paranoia; depression, or suicidal thoughts; anxiety, agitation, restlessness, or nervousness; confusion, delirium, disorientation, or disturbances in attention; insomnia or nightmares, memory impairment. Attempted or completed suicide have been reported, especially in patients with a medical history of depression, or an underlying risk factor for depression. These reactions may occur following the first dose. If these reactions occur in patients receiving Levofloxacin in 5% Dextrose Injection, discontinue Levofloxacin in 5% Dextrose Injection and institute appropriate measures.   
  
Central Nervous System Adverse Reactions of Seizures, Increased Intracranial Pressure, and Tremors   
Fluoroquinolones, including Levofloxacin in 5% Dextrose Injection, have been associated with an increased risk of seizures (convulsions), increased intracranial pressure (including pseudotumor cerebri), tremors, and lightheadedness. As with other fluoroquinolones, Levofloxacin in 5% Dextrose Injection should be used with caution in patients with a known or suspected central nervous system (CNS) disorder that may predispose them to seizures or lower the seizure threshold (e.g., severe cerebral arteriosclerosis, epilepsy) or in the presence of other risk factors that may predispose them to seizures or lower the seizure threshold (e.g., certain drug therapy, renal dysfunction). If these reactions occur in patients receiving Levofloxacin in 5% Dextrose Injection, discontinue Levofloxacin in 5% Dextrose Injection and institute appropriate measures. [see Adverse Reactions (6),Drug Interactions( 7.4,7.5), Patient Counseling Information (17)].
We plan to perform an extensive study of the sympathetic nervous system activity in heart failure patients with an ICD. The SNS activity will be measured directly by a recording of the muscle sympathetic nerve activity and indirectly by post processing of 24-hour Holter recording, catecholamine levels assessment, and spontaneous baroreflex sensitivity. A global assessment of the patients status will also be realised. Patients will be followed for one year. During follow up, this cohort will be divided into two groups according to the occurrence or not of an appropriate shock. We assume that an appropriate shock is a surrogate marker for sudden cardiac death. We plan to compare the autonomic nervous system activity in both groups of patients in order to identify a score able to detect heart failure patients at high risk for sudden cardiac death.
BACKGROUND: The incidence of dysnatremia in children with acute gastritis/gastroenteritis varies, and factors associated with either dysnatremia or hyponatremia at presentation have not been identified clearly.
METHODS: This retrospective study included patients aged 1 month to 18 years hospitalized for community-acquired acute gastritis/gastroenteritis from January to October 2016. Factors associated with dysnatremia at presentation were identified using multivariable analysis.
RESULTS: Among the 304 children included, the median age was 2.2 (1.0, 4.2) years. The incidence of dysnatremia at presentation was 17.1% (hyponatremia 15.8%; hypernatremia 1.3%). Patients who had moderate (p = 0.03) and severe dehydration (p = 0.04) and presented with vomiting and diarrhea simultaneously (p = 0.03) were associated with dysnatremia at presentation. Patients presented with vomiting and diarrhea simultaneously was associated with hyponatremia at presentation (p = 0.02).
CONCLUSIONS: Dysnatremia was common in children with acute gastritis/gastroenteritis. Moderate to severe dehydration and the presence of vomiting and diarrhea simultanously were significantly associated with dysnatremia at presentation. Furthermore, presenting with vomiting and diarrhea silmutaneously was associated with hyponatremia at presentation. Serum electrolytes should be monitored in patients with those conditions.